MX2022016212A - Profármacos de tripamina. - Google Patents

Profármacos de tripamina.

Info

Publication number
MX2022016212A
MX2022016212A MX2022016212A MX2022016212A MX2022016212A MX 2022016212 A MX2022016212 A MX 2022016212A MX 2022016212 A MX2022016212 A MX 2022016212A MX 2022016212 A MX2022016212 A MX 2022016212A MX 2022016212 A MX2022016212 A MX 2022016212A
Authority
MX
Mexico
Prior art keywords
tryptamine
prodrugs
zwitterions
depression
symbol
Prior art date
Application number
MX2022016212A
Other languages
English (en)
Spanish (es)
Inventor
Nathan Bryson
Original Assignee
Reunion Neuroscience Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reunion Neuroscience Canada Inc filed Critical Reunion Neuroscience Canada Inc
Publication of MX2022016212A publication Critical patent/MX2022016212A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022016212A 2020-06-30 2021-06-30 Profármacos de tripamina. MX2022016212A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063045901P 2020-06-30 2020-06-30
US202063109095P 2020-11-03 2020-11-03
PCT/CA2021/050907 WO2022000091A1 (en) 2020-06-30 2021-06-30 Tryptamine prodrugs
US17/364,047 US11292765B2 (en) 2020-06-30 2021-06-30 Tryptamine prodrugs

Publications (1)

Publication Number Publication Date
MX2022016212A true MX2022016212A (es) 2023-03-02

Family

ID=79032374

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016212A MX2022016212A (es) 2020-06-30 2021-06-30 Profármacos de tripamina.

Country Status (14)

Country Link
US (4) US11292765B2 (cg-RX-API-DMAC7.html)
EP (2) EP4172145B1 (cg-RX-API-DMAC7.html)
JP (2) JP7702654B2 (cg-RX-API-DMAC7.html)
KR (2) KR102829078B1 (cg-RX-API-DMAC7.html)
CN (3) CN119285527A (cg-RX-API-DMAC7.html)
AU (1) AU2021302692A1 (cg-RX-API-DMAC7.html)
CA (1) CA3181092A1 (cg-RX-API-DMAC7.html)
DK (1) DK4172145T3 (cg-RX-API-DMAC7.html)
FI (1) FI4172145T3 (cg-RX-API-DMAC7.html)
IL (2) IL299506B2 (cg-RX-API-DMAC7.html)
LT (1) LT4172145T (cg-RX-API-DMAC7.html)
MX (1) MX2022016212A (cg-RX-API-DMAC7.html)
PT (1) PT4172145T (cg-RX-API-DMAC7.html)
WO (1) WO2022000091A1 (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022550463A (ja) 2019-10-01 2022-12-01 エンピリアン ニューロサイエンス, インコーポレイテッド トリプタミン発現を調整する真菌の遺伝子操作
MX2022009527A (es) 2020-02-04 2022-11-16 Mindset Pharma Inc Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.
AU2021215709A1 (en) 2020-02-04 2022-09-01 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
DK4172145T3 (da) * 2020-06-30 2026-07-20 Reunion Neuroscience Inc Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression
WO2022040802A1 (en) * 2020-08-26 2022-03-03 Magicmed Industries Inc. Glycosylated psilocybin derivatives and methods of using
WO2022120181A1 (en) * 2020-12-03 2022-06-09 Mydecine Innovations Group Inc. Novel psilocin analog compositions and methods of synthesizing the same
JP2024500397A (ja) * 2020-12-18 2024-01-09 コンパス パスファインダー リミテッド 治療用途のための修飾インドールアルカロイド
EP4126857A1 (en) 2021-01-15 2023-02-08 Beckley Psytech Limited Ergoline analogues
EP4277894A1 (en) 2021-01-15 2023-11-22 Beckley Psytech Limited Tryptamine analogues
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
JP2024520832A (ja) 2021-06-08 2024-05-24 エンセオジェニックス バイオサイエンシズ, インコーポレイテッド セロトニン受容体のジメトキシフェニルアルキルアミン活性化剤
AU2022309017A1 (en) 2021-07-07 2024-01-25 Terran Biosciences Inc. N,n-dimethyltryptamine and related psychedlics and uses thereof
WO2023018864A1 (en) 2021-08-12 2023-02-16 Psilosterics, Llc Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same
KR20240065084A (ko) * 2021-08-20 2024-05-14 테란 바이오사이언시스 인코포레이티드 사일로신의 전구약물 및 유도체 및 그의 용도
WO2023086962A1 (en) 2021-11-12 2023-05-19 Terran Biosciences Inc. Psilocybin and o-acetylpsilocin, salts and solid state forms thereof
AU2022408191B2 (en) * 2021-12-10 2025-05-15 Caamtech, Inc. Psilocybin derivatives
US20250051278A1 (en) * 2021-12-14 2025-02-13 Reunion Neuroscience, Inc. Tryptamine prodrugs
CA3242479A1 (en) 2021-12-27 2023-07-06 Atai Therapeutics, Inc. AMINOTERALINE SEROTONIN RECEPTOR ACTIVATORS
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023130075A2 (en) 2021-12-31 2023-07-06 Empyrean Neuroscience, Inc. Genetically modified organisms for producing psychotropic alkaloids
US20250066299A1 (en) * 2022-01-06 2025-02-27 Terran Biosciences Inc. Salts and solid forms of 4-hydroxy-n,n-diisopropyltryptamine hemi-glutarate and hemi-succinate
WO2023147423A1 (en) * 2022-01-28 2023-08-03 Miralogx Llc Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US20250186369A1 (en) * 2022-03-07 2025-06-12 Drexel University Compounds, compositions, and methods for treating, ameliorating, and/or prventing cocaine use disorder
AU2023235712A1 (en) * 2022-03-18 2024-11-07 Enveric Biosciences Canada Inc. C4-substituted tryptamine derivatives and methods of using
US12065404B2 (en) * 2022-03-18 2024-08-20 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
EP4493541A4 (en) * 2022-03-18 2026-02-25 Enveric Biosciences Canada Inc TRYPTAMINE DERIVATIVES SUBSTITUTED BY C4-CARBOXYLIC ACID AND METHODS OF USE
AU2022447256A1 (en) * 2022-03-18 2024-11-07 Enveric Biosciences Canada Inc. C4-carbonothioate-substituted tryptamine derivatives and methods of using
AU2023254841B2 (en) * 2022-04-13 2025-10-23 Caamtech, Inc. Tryptamine derivatives
CN115521240B (zh) * 2022-06-01 2024-05-28 杭州奥泰生物技术股份有限公司 一种二甲基色胺半抗原和人工抗原及其制备方法与应用
AU2023313326A1 (en) * 2022-07-27 2024-12-19 Reconnect Labs Ag Highly soluble formulations of harmine
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
CN116283885B (zh) * 2022-12-01 2025-02-14 杭州奥泰生物技术股份有限公司 一种帕罗西汀半抗原和人工抗原及其制备方法与应用
WO2024145719A1 (en) * 2023-01-05 2024-07-11 Reunion Neuroscience Inc. Improved pharmacokinetics of tryptamine prodrugs
WO2024178051A2 (en) * 2023-02-22 2024-08-29 Caamtech, Inc. Tryptamine derivatives
US12343319B2 (en) 2023-05-01 2025-07-01 Atai Therapeutics, Inc. Compositions and methods for treatment of diseases and disorders
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2025099725A1 (en) * 2023-11-09 2025-05-15 Hadasit Medical Research Services And Development Ltd. Conjugates and uses thereof
WO2025238416A1 (en) * 2024-05-16 2025-11-20 Mindset Pharma Inc. Indole derivatives, uses and compositions thereof
WO2025250900A1 (en) * 2024-05-30 2025-12-04 Caamtech, Inc. 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate
WO2026024591A1 (en) * 2024-07-22 2026-01-29 Reunion Neuroscience, Inc. Tryptamine prodrug solid forms
WO2026128398A1 (en) * 2024-12-09 2026-06-18 Reunion Neuroscience, Inc. Treatment of adjustment disorder

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3075992A (en) 1958-09-12 1963-01-29 Sandoz Ltd Esters of indoles
NL121067C (cg-RX-API-DMAC7.html) 1958-09-12
CH373381A (de) 1959-07-13 1963-11-30 Sandoz Ag Verfahren zur Herstellung neuer basischer Indol-Derivate
CH386422A (de) 1960-03-30 1965-01-15 Sandoz Ag Verfahren zur Herstellung neuer Ester der Indol-Reihe
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
WO1995006638A1 (en) * 1993-09-01 1995-03-09 Allelix Biopharmaceuticals Inc. Tryptamine analogs with 5-ht1d selectivity
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2006047032A2 (en) 2004-09-27 2006-05-04 Organix, Inc. Indole compounds useful as serotonin selective agents
US8809261B2 (en) 2008-10-31 2014-08-19 Elsohly Laboratories, Incorporated Compositions containing delta-9-THC-amino acid esters and process of preparation
US20180021326A1 (en) * 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US12616706B2 (en) * 2019-03-07 2026-05-05 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
MX2022009527A (es) 2020-02-04 2022-11-16 Mindset Pharma Inc Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.
DK4172145T3 (da) * 2020-06-30 2026-07-20 Reunion Neuroscience Inc Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression
JP2024500397A (ja) * 2020-12-18 2024-01-09 コンパス パスファインダー リミテッド 治療用途のための修飾インドールアルカロイド

Also Published As

Publication number Publication date
KR102829078B1 (ko) 2025-07-04
IL320601A (en) 2025-07-01
CN115867533B (zh) 2024-07-23
EP4172145A1 (en) 2023-05-03
US20210403425A1 (en) 2021-12-30
IL299506B2 (en) 2025-10-01
JP7702654B2 (ja) 2025-07-04
IL299506A (en) 2023-02-01
IL299506B1 (en) 2025-06-01
EP4172145A4 (en) 2024-08-21
LT4172145T (lt) 2026-07-27
US20250129023A1 (en) 2025-04-24
CN115867533A (zh) 2023-03-28
KR20230028543A (ko) 2023-02-28
JP7864902B2 (ja) 2026-05-25
CN119285527A (zh) 2025-01-10
DK4172145T3 (da) 2026-07-20
US11292765B2 (en) 2022-04-05
EP4786000A2 (en) 2026-08-05
KR20250103811A (ko) 2025-07-07
FI4172145T3 (fi) 2026-07-22
JP2023531311A (ja) 2023-07-21
AU2021302692A1 (en) 2023-01-19
EP4172145B1 (en) 2026-05-13
PT4172145T (pt) 2026-07-17
US20250382267A1 (en) 2025-12-18
CN119285526A (zh) 2025-01-10
CA3181092A1 (en) 2022-01-06
WO2022000091A1 (en) 2022-01-06
US20220177427A1 (en) 2022-06-09
JP2025143280A (ja) 2025-10-01

Similar Documents

Publication Publication Date Title
CO2021011188A2 (es) Compuesto heterocíclico y su uso
CO2020001879A2 (es) Compuesto heterocíclico y su uso
CO2018008705A2 (es) Compuestos de piperidina sustituido y su uso
MX2023000693A (es) Inhibidor de egfr.
ECSP13012478A (es) Compuesto heterocíclico y su uso
MX2013009957A (es) Agente de control de endoparasitos.
CO2025005865A2 (es) Compuesto heterocíclico
CR10564A (es) Compuestos cíclicos fusionados
MX2017016413A (es) Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem.
CO6491037A2 (es) Derivados de pirazinooxazepina
CO6260091A2 (es) Derivados de iminopiridina y su uso
UY39150A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
CL2025001563A1 (es) Compuesto heterocíclico y uso del mismo
CO2022010011A2 (es) Derivado de amino arilo novedoso útil como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo
MX2019002314A (es) Compuesto de 1-acetil-fenil urea, y uso del mismo.
PE20191788A1 (es) Compuesto de n-(4-piridil)nicotinamida o sal del mismo
AR109406A1 (es) Compuesto de 1-fenil-3-carbamoilurea y su uso
ECSP23088732A (es) Moduladores de trex1
MX2019010967A (es) Agente terapeutico o profilactico para neuropatias perifericas.
CO2025012357A2 (es) Compuestos heterocíclicos macrocíclicos y sus usos
AR132690A1 (es) Antagonista del receptor de melanocortina 2
CO2019012270A2 (es) Compuesto heterocíclico
AR109405A1 (es) Compuestos de fenilurea y su uso
CO2024007757A2 (es) Sistema generador de aerosol
AR109408A1 (es) Compuesto de 3-piridiloxianilina y su uso